Predictive Oncology Inc.
POAI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.42 | 1.17 | 0.22 |
| FCF Yield | -16.06% | -2.93% | -0.46% | -4.54% |
| EV / EBITDA | -0.15 | -63.59 | -76.33 | -44.18 |
| Quality | ||||
| ROIC | 4.33% | -580.39% | -129.03% | -108.80% |
| Gross Margin | -130.96% | -579.38% | 59.10% | 52.48% |
| Cash Conversion Ratio | 0.02 | 1.68 | 0.33 | 1.45 |
| Growth | ||||
| Revenue 3-Year CAGR | -25.63% | -11.60% | -2.01% | 3.22% |
| Free Cash Flow Growth | 50.25% | -339.46% | 75.14% | -33.45% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | -0.89 | 0.55 | -0.90 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.43 | 0.99 | 0.75 |
| Cash Conversion Cycle | -28,215.65 | -5,669.53 | -2,282.25 | -124.77 |